Nowotny A, Behling U H
Klin Wochenschr. 1982 Jul 15;60(14):735-9. doi: 10.1007/BF01716566.
The findings reported here indicate that toxic reactions to endotoxin do not have to be part of the mechanisms leading to clinically improved status of patients or of experimental animals. It seems to be possible to mobilize the host defenses without the unwanted or dangerous side effects which were encountered during fever therapy. For the demonstration of activated host defenses, several experimental models are available. Non-specific resistance to bacterial infections, to lethal irradiation or to experimental challenge with viable tumors are clear manifestations of enhanced capacity of the endotoxin-treated host to compensate for the induced damage, or to cope with an otherwise overwhelming number of pathogenic cells. Immunopotentiation is obviously one of the contributing factors in some of the above parameters. How these results are applicable to human therapy remains to be seen. Such use of endotoxin derivatives, or better, the mediators of beneficial endotoxic effects, must wait until we learn more about the nature of the alternating positive and negative effects of endotoxin application. The importance of the proper timing of such a therapeutic modality cannot be overemphasized.
此处报告的研究结果表明，内毒素的毒性反应不一定是导致患者或实验动物临床状况改善的机制的一部分。似乎有可能调动宿主防御系统，而不会出现发热疗法期间遇到的不良或危险副作用。为了证明宿主防御系统被激活，有几种实验模型可用。对细菌感染、致死性辐射或活肿瘤实验性攻击的非特异性抵抗力，是内毒素处理过的宿主增强补偿诱导损伤或应对原本压倒性数量致病细胞能力的明显表现。免疫增强显然是上述某些参数中的一个促成因素。这些结果如何应用于人类治疗还有待观察。这种内毒素衍生物的使用，或者更好的是有益内毒素效应的介质的使用，必须等到我们更多地了解内毒素应用的正负交替效应的性质之后。这种治疗方式的正确时机的重要性再怎么强调也不为过。
